Covid-19 roundup: Re­gen­eron/Roche an­ti­body com­bo keeps its punch 8 months in; WaPo: Pfiz­er ex­pect­ed to seek au­tho­riza­tion for boost­ers for all adults

Push­ing hard to carve out a block­buster mar­ket ahead of the grow­ing com­pe­ti­tion among an­ti-Covid treat­ments, re­searchers from Re­gen­eron and Roche are tout­ing new da­ta un­der­scor­ing the dura­bil­i­ty of their casiriv­imab/imde­vimab com­bo now known as RE­GEN-COV — demon­strat­ing long-term pro­tec­tion against the coro­n­avirus from just one dose.

The part­ners re­leased more re­sults to­day from a Phase III tri­al joint­ly run with NI­AID — look­ing at a sin­gle dose of the in­ves­ti­ga­tion­al an­ti­body com­bo to pre­vent Covid-19 in un­in­fect­ed in­di­vid­u­als.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER